|
業務類別
|
Biotechnology |
|
業務概覽
|
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States. |
| 公司地址
| 9804 Medical Center Drive, Rockville, MD, USA, 20850 |
| 電話號碼
| +1 240 552-8181 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.regenxbio.com |
| 員工數量
| 353 |
| Mr. Mitchell Chan |
Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer |
美元 141.35K |
05/03/2026 |
| Mr. Stephen Pakola, M.D. |
Executive Vice President and Chief Medical Officer |
美元 518.08K |
08/04/2025 |
| Dr. Olivier Danos, PhD |
Executive Vice President and Chief Scientific Officer |
美元 522.35K |
08/04/2025 |
| Mr. Patrick J. Christmas |
Executive Vice President, Chief Strategy Officer and Chief Legal Officer |
美元 500.87K |
08/04/2025 |
| Mr. Curran Simpson |
Director, President and Chief Executive Officer |
美元 571.72K |
05/03/2026 |
|
|
| Ms. Jennifer Zachary |
Independent Director |
05/03/2026 |
| Dr. Jean Bennett, M.D.,Pd.D |
Independent Director |
05/03/2026 |
| Mr. Allan M. Fox |
Director |
05/03/2026 |
| Dr. Alexandra Glucksmann, PhD |
Independent Director |
05/03/2026 |
| Mr. Daniel Tasse |
Lead Independent Director |
05/03/2026 |
| Mr. George V. Migausky |
Independent Director |
05/03/2026 |
| Dr. David C. Stump,M.D. |
Independent Director |
05/03/2026 |
| Mr. Curran Simpson |
Director, President and Chief Executive Officer |
05/03/2026 |
| Mr. Kenneth T. Mills |
Chairman of the Board |
05/03/2026 |
| Dr. Argeris N. Karabelas, PhD |
Independent Director |
05/03/2026 |
|
|
|
|
